WCLC 2022

Sugemalimab consolidation improved progression-free survival, when compared with placebo, in patients with unresectable, stage III non-small cell lung cancer.

Adding nivolumab to neoadjuvant platinum-based chemotherapy can improve survival in patients with stage IIIA-B non-small cell lung cancer, new data suggest.